Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
761-780 of 847 trials

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Lung Cancer Treatment: Divarasib and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if this new approach improves survival and quality of life compared to standard treatments.

Advanced Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Leber Congenital Amaurosis: Sepofarsen Treatment Study

We are investigating a new treatment for people with Leber Congenital Amaurosis caused by a specific genetic mutation. The study will assess how well it improves vision and its safety over time.

Leber's Congenital Amaurosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Ulcerative Colitis: Tofacitinib's Impact on Blood Clotting

We are studying how tofacitinib affects blood clotting and platelet function in patients with ulcerative colitis. This trial also compares its effects to other treatments and collects samples for future research.

Ulcerative Colitis3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyHematology

Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

Myoclonic-Astatic Epilepsy>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Ulcerative Rectal Colitis: Tofacitinib Response Study

We are researching what factors may predict how well patients with ulcerative rectal colitis respond to Tofacitinib therapy. This could help improve treatment strategies for better patient care.

Ulcerative Colitis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Ulcerative Colitis: MK-7240 Treatment Study

We are studying MK-7240 to see if it helps people with moderately to severely active ulcerative colitis achieve remission. The trial will also evaluate the safety and effectiveness of this new treatment compared to a placebo.

Ulcerative Colitis1-2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterology

Dravet Syndrome: EPX-100 Treatment Study

We are testing a new medication, EPX-100, to see if it helps children and adults with Dravet Syndrome manage their seizures better than a placebo. This study aims to find out if this treatment can be a useful addition to their current care.

Dravet Syndrome3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesNeurologyPediatrics

Gastroesophageal Cancer: Sertraline with Immunochemotherapy

We are studying whether adding sertraline can enhance treatment responses in patients with advanced gastroesophageal cancer receiving immunochemotherapy. The trial also looks at safety, quality of life, and depression during treatment.

Gastroesophageal Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPsychiatry

Blood Cancers: Sonrotoclax Safety Study

We are investigating new dosing schedules for Sonrotoclax in adults with blood cancers. The study aims to understand the safety and tolerability of this treatment approach.

Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Sclerosis: Ozanimod Treatment Study

We are investigating how ozanimod affects inflammation in the brain and spinal cord for individuals with Multiple Sclerosis. This study aims to understand its potential benefits and any side effects.

Relapsing Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Ulcerative Colitis and Crohn’s Disease: Long-term Study of Zasocitinib

We are investigating the long-term safety and effectiveness of oral zasocitinib in adults with moderately to severely active ulcerative colitis and Crohn’s disease. This study is for those who have responded to treatment in previous trials.

Ulcerative ColitisCrohn's Disease>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

SGLT-2 Inhibitors for Elderly Patients with Type 2 Diabetes

We are comparing different SGLT-2 inhibitors to see which helps elderly patients manage their blood sugar levels safely. The study looks at effectiveness and potential side effects over time.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDiabetologyEndocrinology

Narcolepsy and Idiopathic Hypersomnia: ORX750 Study

We are testing a new medication, ORX750, to see if it is safe and well-tolerated in people with narcolepsy and idiopathic hypersomnia. This study will help us understand how the drug works in the body.

Narcolepsy with CataplexyIdiopathic Hypersomnia3-6 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology